Lenalidomide Form H1 Crystallization for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current forms of lenalidomide exhibit variability in stability and physical properties, influencing pharmaceutical properties such as handling, dissolution, and shelf life, necessitating the discovery of a stable and reproducible crystalline form suitable for pharmaceutical applications.
Innovation Solution
A novel crystalline Form H1 of lenalidomide is developed, characterized by specific X-ray diffraction peaks, along with a process involving suspension in N-methylpyrrolidone, heating, cooling, and solvent addition, and subsequent isolation, which also includes the preparation of its N-methylpyrrolidone solvate as an intermediate for other polymorphs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing polymorphic forms of lenalidomide are used, then the drug can be manufactured and processed, but the stability and physical properties vary significantly, affecting shelf life and handling
Solution Approach 1:
The patent applies parameter changes by modifying the crystallization conditions, specifically using N-methylpyrrolidone as a solvent and controlling temperature parameters (heating above 50°C, cooling below 15°C) to obtain a novel crystalline form with consistent physical properties and enhanced stability
Solution Approach 2:
The patent utilizes phase transitions through the crystallization process, where lenalidomide transitions from a suspension state through heating and cooling cycles to form a stable crystalline structure with defined X-ray diffraction patterns, ensuring reproducible physical properties
2Adaptability or versatility
If multiple polymorphic forms are investigated, then comprehensive understanding of the drug's solid forms is achieved, but the complexity of characterization and selection increases
Solution Approach 1:
The patent extracts the essential characteristics of the novel crystalline form by identifying specific X-ray diffraction peaks (2θ positions at 8.5, 14.0, 14.5, 15.6, 16.1, 17.1, 17.6, 19.6, 21.6, 22.8, and 25.3 ± 0.2 degrees), which serve as unique identifiers for this polymorph, simplifying future characterization and selection
3Reliability
If a novel crystalline form is developed, then stability and reproducibility are enhanced, but additional research and development time is required
Solution Approach 1:
The patent performs preliminary action by establishing a detailed crystallization protocol with specific temperature parameters and solvent quantities before full-scale production, including preliminary characterization through X-ray diffraction, DSC, and IR spectroscopy, which accelerates future development and reduces time for scale-up
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel crystalline Form H1 of lenalidomide demonstrates enhanced stability and reproducibility, improving pharmaceutical processing and shelf life, and can be formulated into various pharmaceutical compositions with acceptable excipients.
Implementation Method 1
suspending lenalidomide in N-methylpyrrolidone; heating the suspension obtained in step (a) at above 50°C
Implementation Method 2
cooling the solution obtained in step (b) at below 15°C; isolating lenalidomide N-methylpyrrolidone solvate
Implementation Method 3
characterized by peaks in the powder x-ray diffraction spectrum having 2θ angle positions at 8.5, 14.0, 14.5, 15.6, 16.1, 17.1, 17.6, 19.6, 21.6, 22.8 and 25.3 ± 0.2 degrees
Data Source
Figure 1
Figure 2
AI summary
The present invention provides a novel crystalline Form of lenalidomide, process for its preparation and pharmaceutical compositions comprising it. The present invention also provides a novel N-methylpyrrolidone solvate of lenalidomide and process for its preparation.